| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 9, 2025
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first closed-loop DBS system for...
-
Feb 24, 2025
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland, Feb. 24, 2025...
Jan 8, 2024Rechargeable neurostimulator joins the Medtronic Percept™ family – the first and only deep brain stimulation system with sensing, directionality, and advanced programming. DUBLIN, Jan. 8, 2024...
-
Jan 12, 2022
Sessions will include DTM™ SCS endurance therapy 3-month outcomes for patients with chronic back and leg pain DUBLIN, Jan. 12, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in...
Jun 7, 2021The SenSight™ Directional Lead System Was Designed to Enable Precision, Personalization and Enhanced Patient ComfortMedtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) approval and first U.S. implants of the SenSight™ Directional Lead...
-
Mar 22, 2021
This First-of-its-Kind Directional Lead Combines the Benefits of Directionality with the Power of Sensing DUBLIN, March 22, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in...
-
Jan 14, 2021
ADAPT-PD Global Study Designed to Demonstrate Safety & Efficacy of Automated Therapy Which Responds to Brain Signals in Parkinson's Disease Patients DUBLIN, Jan. 14, 2021 /PRNewswire/ -- Medtronic...
-
Jun 25, 2020Next-Generation Technology Makes Percept™ the First and Only DBS System with Ability to Capture Patient-Specific Brain Signals
DUBLIN, June 25, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announces it received Food and Drug Administration (FDA) approval for the...
-
Jan 9, 2020This Next-Generation DBS Technology Allows Physicians to Review Patient-Specific Brain Signals, Enabling More Personalized, Data-Driven Neurostimulation Treatment for Patients
DUBLIN, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the CE (Conformité Européenne) Mark for Percept™ PC neurostimulator; it is the only Deep Brain Stimulation...
-
Oct 30, 2019System Offers at Home Therapy Management for DBS patients Using Patient-Friendly Consumer Technology
DUBLIN and SAN JOSE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the U.S. launch of its advanced Patient Programmer technology for Deep Brain Stimulation...
-
Feb 20, 2019With Official Launch and First Implant, Several Health Insurers Now Consider DBS Therapy for Epilepsy a Covered Indication
DUBLIN - February 20, 2019 - Medtronic plc (NYSE:MDT) today announced both the U.S. launch of Deep Brain Stimulation (DBS) for medically-refractory epilepsy and the first commercially implanted...
-
Jun 13, 2018FDA Approved, DBS Clinician Programmer Optimizes the Programming Experience By Addressing Day-to-Day Clinical Management Challenges
DUBLIN - June 13, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) recently approved its state-of-the art...
-
May 1, 2018Medtronic Receives FDA Approval for Deep Brain Stimulation Therapy for Medically Refractory Epilepsy7-Year Data from the SANTE Trial Showed Median Seizure Frequency Reduction of 75 percent in Patients with Drug-Resistant Epilepsy with Partial-Onset Seizures Receiving DBS Therapy.
DUBLIN - May 1, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval for Medtronic'